Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection

PR Newswire April 23, 2018

Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan

PR Newswire March 7, 2018

Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results

PR Newswire February 22, 2018

Synthetic Biologics, Inc. to Host Earnings Call

Accesswire February 22, 2018

Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018

PR Newswire February 15, 2018

Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference

PR Newswire January 2, 2018

Synthetic Biologics Announces Management Changes

PR Newswire December 5, 2017

Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results

PR Newswire November 1, 2017

Synthetic Biologics, Inc. to Host Earnings Call

Accesswire November 1, 2017

Biotech Stocks on Investors' Radar -- Synthetic Biologics, 22nd Century, Abeona Therapeutics, and Aeterna Zentaris

PR Newswire October 31, 2017

Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017

PR Newswire October 25, 2017

Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing

PR Newswire September 12, 2017

Synthetic Biologics, Inc. Provides Company Overview and Update on Clinical Development in New SNNLive Video Interview with StockNewsNow.com

Accesswire September 6, 2017

Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017

PR Newswire August 29, 2017

Daily Technical Summary Reports on Biotech Stocks -- Axovant Sciences, Ampio Pharma, ImmunoCellular Therapeutics, and Synthetic Biologics

PR Newswire August 9, 2017

Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results

PR Newswire August 3, 2017

Investor Network: Synthetic Biologics, Inc. to Host Earnings Call

Accesswire August 3, 2017

Synthetic Biologics to Report Second Quarter 2017 Operational Highlights and Financial Results on August 3, 2017

PR Newswire July 27, 2017

Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire June 27, 2017

SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection

PR Newswire May 11, 2017